In last trading session, Moderna Inc (NASDAQ:MRNA) saw 6.75 million shares changing hands with its beta currently measuring 1.66. Company’s recent per share price level of $54.10 trading at -$0.72 or -1.31% at ring of the bell on the day assigns it a market valuation of $20.80B. That closing price of MRNA’s stock is at a discount of -215.1% from its 52-week high price of $170.47 and is indicating a discount of -1.33% from its 52-week low price of $54.82. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.48 million shares which gives us an average trading volume of 4.81 million if we extend that period to 3-months.

For Moderna Inc (MRNA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.63. Splitting up the data highlights that, out of 17 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 12 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.89 in the current quarter.

Moderna Inc (NASDAQ:MRNA) trade information

Upright in the red during last session for losing -1.31%, in the last five days MRNA remained trading in the red while hitting it’s week-highest on Monday, 10/14/24 when the stock touched $54.10 price level, adding 8.24% to its value on the day. Moderna Inc’s shares saw a change of -45.60% in year-to-date performance and have moved -7.19% in past 5-day. Moderna Inc (NASDAQ:MRNA) showed a performance of -20.46% in past 30-days. Number of shares sold short was 31.32 million shares which calculate 5.03 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 145 to the stock, which implies a rise of 62.69% to its current value. Analysts have been projecting 55 as a low price target for the stock while placing it at a high target of 304. It follows that stock’s current price would drop -1.66% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1.66% for stock’s current value.

Moderna Inc (MRNA) estimates and forecasts

Statistics highlight that Moderna Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -46.65% of value to its shares in past 6 months, showing an annual growth rate of 19.38% while that of industry is 17.20. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -52.80% from the last financial year’s standing.

15 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 1.23B for the same. And 15 analysts are in estimates of company making revenue of 1.59B in the next quarter. Company posted 1.83B and 2.81B of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -20.02% during past 5 years.

Moderna Inc (NASDAQ:MRNA)’s Major holders

Insiders are in possession of 9.52% of company’s total shares while institution are holding 72.09 percent of that, with stock having share float percentage of 79.67%. Investors also watch the number of corporate investors in a company very closely, which is 72.09% institutions for Moderna Inc that are currently holding shares of the company. BAILLIE GIFFORD & CO is the top institutional holder at MRNA for having 43.45 million shares of worth $5.16 billion. And as of 2024-06-30, it was holding 11.3741 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 39.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.3568 of outstanding shares, having a total worth of $4.7 billion.